EyePoint DURAVYU Phase 3 Trial Fails
Analysis based on 33 articles · First reported Aug 21, 2026 · Last updated Sep 03, 2026
EyePoint's stock collapsed by about 67% on the trial failure, erasing roughly 70% of shareholder value. The event also triggered multiple securities investigations, potentially leading to litigation costs and reputational damage for the company.
On August 17, 2026, EyePoint Pharmaceuticals announced topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU (vorolanib intravitreal insert) in wet age-related macular degeneration. The trial failed to meet its prespecified primary endpoint of change in best-corrected visual acuity versus on-label aflibercept (Regeneron's Eylea) in the full dataset. The company highlighted favorable secondary results, including a 42% reduction in treatment burden, and an ad hoc analysis excluding a 4% asymmetric patient cohort, but the primary endpoint failure stood. Following the announcement, EyePoint's stock plummeted nearly 67%, wiping out roughly 70% of market value in a single session. Several law firms, including Pomerantz LLP, Levi & Korsinsky, and Kessler Topaz Meltzer & Check, launched investigations into potential securities fraud, focusing on whether EyePoint adequately disclosed trial risks and the asymmetric patient cohort despite repeatedly describing the program as 'derisked' on earnings calls from Q4 2024 through Q1 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard